Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sept. 3, 2015  StemProtein LLC, a leading ... spinout of Stemedica Cell Technologies Inc., announced today ... as CEO of StemProtein. Silberg will help advance ... preserving Stem Cell Factors (SCFs), a significant consumer ... the pharmaceutical and biopharmaceutical industries with substantial executive ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... non-invasive hydration monitoring wearable early 2016. , The device, called the Halo ... proprietary optical and electrical sensing technology. These sensors track trending interstitial fluid levels ...
(Date:9/2/2015)... 2, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... and Companies" to their offering. ... based on technologies and applications. The report starts ... for estimation of markets. Technologies include array comparative ...
Breaking Biology Technology:StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... Investigating programmed cell death , Wei-ping Yang ... ,Stratagene , The apoptotic response is a complex ... of genes that interact with and respond to ... ,sets that are specific for genes ...
... pathway activation , Li Xu Tim Sanchez ... Stratagenes PathDetect in vivo signal transduction pathway,reporting systems ... activation of signal,transduction pathways. To expand the utility ... and pFA-Elk1 plasmids with new, improved fusion,trans-activator plasmids. ...
... with TKB1 competent cells , David ... for Molecular Biology and Biotechnology, McMaster University,Ontario, ... bacteria are used to affinity purify,cellular proteins, ... on,the ErbB2/Neu receptor tyrosine kinase (RTK). This ...
Cached Biology Technology:RT-PCR Primers for the Study of Apoptosis 2RT-PCR Primers for the Study of Apoptosis 3RT-PCR Primers for the Study of Apoptosis 4RT-PCR Primers for the Study of Apoptosis 5RT-PCR Primers for the Study of Apoptosis 6RT-PCR Primers for the Study of Apoptosis 7Improved Vectors for PathDetect Trans-Reporting Systems 2Improved Vectors for PathDetect Trans-Reporting Systems 3Improved Vectors for PathDetect Trans-Reporting Systems 4Improved Vectors for PathDetect Trans-Reporting Systems 5TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 2TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 3TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 4TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins 5
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... ITHACA, N.Y. - A new study of maize has ... the genome. New techniques may allow breeders and researchers to ... new varieties that were not easily possible before. Publishing ... researchers, whose senior and first author are at Cornell, have ...
... COLLEGE PARK, Md.-John Fisher, associate professor in the Fischell ... the 2009 Bioscience Research and Technology Review Day with ... other types of tissue for implantation. Fisher,s technology ... minute pitch by faculty members and graduate students at ...
... the first time, scientists have successfully used a method called ... for a mendelian disorder. Mendelian disorders, such as ... one or more mutations in a single gene, typically a ... code for proteins taken together are called the exome. The ...
Cached Biology News:New map of variation in maize genetics holds promise for developing new varieties 2Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome 2Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome 3
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
HSPBP1 Antibody...
... advanced RACE (rapid amplification of cDNA ends) ... full-length 5' and 3' cDNA ends. The ... Reverse Transcriptase (RT) for improved amplification of ... complex mRNA. The RNase H portion of ...
Biology Products: